<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496648</url>
  </required_header>
  <id_info>
    <org_study_id>H-18009651</org_study_id>
    <nct_id>NCT04496648</nct_id>
  </id_info>
  <brief_title>Percutaneous Coronary Intervention Versus Medical Treatment for Stable Angina Pectoris</brief_title>
  <acronym>DANANGINA</acronym>
  <official_title>The Danish Randomized Sham-Controlled Study of Invasive Versus Medical Treatment for Stable Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with ischemic heart disease and symptoms due to lack of oxygen to the heart on&#xD;
      exertion (stable angina pectoris) are usually treated by either percutaneous coronary&#xD;
      intervention (PCI) or optimal medical therapy (OMT) alone. In patients with mild to moderate&#xD;
      coronary artery disease the prognostic impact of PCI is probably limited. Furthermore it is&#xD;
      unclear which treatment is superior in terms of relieving symptoms (PCI or OMT). In this&#xD;
      trial, patients with mild to moderate coronary artery disease will be randomized to PCI or&#xD;
      sham-PCI. All patients will undergo optimal medical therapy. It is hypothesized that PCI is&#xD;
      superior to sham-PCI in patients with stable angina pectoris undergoing optimal medical&#xD;
      therapy in terms of symptom-relief.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic heart disease (IHD) is a major cause of death and disability worldwide. Patients&#xD;
      with ischemic heart disease and symptoms due to lack of oxygen to the heart on exertion&#xD;
      (stable angina pectoris) are usually treated by either percutaneous coronary intervention&#xD;
      (PCI) or optimal medical therapy (OMT) alone. In patients with mild to moderate coronary&#xD;
      artery disease the prognostic impact of PCI is probably limited. Furthermore it is unclear&#xD;
      which treatment is superior in terms of relieving symptoms (PCI or OMT). Both treatments are&#xD;
      effective in terms of reducing symptoms, but come with potential side effects.&#xD;
&#xD;
      PCI has in previous trials failed to show superiority compared to medical therapy in patients&#xD;
      with stable angina pectoris. However, many visually significant lesions do not limit the&#xD;
      blood flow significantly to the heart, and stenting such a lesion only exposes the patient to&#xD;
      the risk of side effects of intervention. In recent years it has therefore become&#xD;
      guideline-recommended practice to perform physiological test to evaluate a potential&#xD;
      stenosis. During an angiography this is most often done using fractional flow reserve (FFR).&#xD;
&#xD;
      This study tests the optimal strategy for treatment of angina-symptoms in patients with&#xD;
      stable pectoris. PCI is performed with modern stent designs and use of intravascular&#xD;
      functional testing (FFR-guided PCI) and compared to sham-PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized patient-blind sham-controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint of strategy success</measure>
    <time_frame>3 months</time_frame>
    <description>Number of patients without angina (freedom from angina) and without hospital admission for intolerable stable angina pectoris, unstable angina pectoris, or acute myocardial infarction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of all-cause death, any myocardial infarction, stroke, major bleeding, and severe drug reaction</measure>
    <time_frame>3 months</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of conversions to PCI for procedural complication (sham-PCI group)</measure>
    <time_frame>3 months</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hospital admission for intolerable stable angina, unstable angina pectoris, or acute myocardial infarction</measure>
    <time_frame>3 months</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in CCS class 1, 2, and 3, respectively, without hospital admission for intolerable stable angina, unstable angina pectoris, or acute myocardial infarction</measure>
    <time_frame>3 months</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically driven coronary revascularization</measure>
    <time_frame>3 months</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CCS class</measure>
    <time_frame>3 months</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antianginal agents</measure>
    <time_frame>3 months</time_frame>
    <description>0, 1, 2, or 3 agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>3 months</time_frame>
    <description>5- level EQ-5D (EQ-5D-5L) questionnaire. Each dimension will be scored from 0-5 where a higher score means a better outcome. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angina-specific quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Seattle Angina Questionnaire 7. Values will range from 0-100 where higher score means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary composite endpoint in the modified intention-to-treat population</measure>
    <time_frame>3 months</time_frame>
    <description>The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CCS class in the modified intention-to-treat population</measure>
    <time_frame>3 months</time_frame>
    <description>The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seattle Angina Questionnaire 7 score in the modified intention-to-treat population</measure>
    <time_frame>3 months</time_frame>
    <description>The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding. Values will range from 0-100 where higher score means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in generic quality of life (EQ-5D-5L) in the modified intention-to-treat population</measure>
    <time_frame>3 months</time_frame>
    <description>The modified intention-to-treat population is comprised of patients who underwent the study procedure and follow-up without overt or formal unblinding. Each dimension will be scored from 0-5 where a higher score means a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Stable Angina</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional PCI and optimal medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham-PCI and optimal medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention</intervention_name>
    <description>Percutaneous coronary intervention with drug-eluting stents and modern techniques</description>
    <arm_group_label>Percutaneous Coronary Intervention</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham-percutaneous coronary intervention</intervention_name>
    <description>Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.</description>
    <arm_group_label>Sham-percutaneous coronary intervention</arm_group_label>
    <other_name>sham-PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Age 18-85 years&#xD;
&#xD;
          -  Patients with stable angina pectoris undergoing elective coronary angiography&#xD;
&#xD;
          -  Canadian Cardiovascular Society (CCS) class 2 or 3&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Lesions in one or more coronary vessels with a diameter &gt;2.5 mm with FFR-values ≤0.80,&#xD;
             and suitable for complete revascularization with PCI.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Contraindication to PCI or dual antiplatelet therapy (DAPT)&#xD;
&#xD;
          -  Use of or indication for oral anticoagulants (OAC) or novel oral anticoagulants (NOAC)&#xD;
&#xD;
          -  Use of clopidogrel&#xD;
&#xD;
          -  Life expectancy of less than 2 years&#xD;
&#xD;
          -  Severe valvular disease&#xD;
&#xD;
          -  Severe comorbidity&#xD;
&#xD;
          -  Acute coronary event within the past 12 months&#xD;
&#xD;
          -  Left ventricular ejection fraction ≤35%.&#xD;
&#xD;
          -  Renal function with estimated glomerular filtration rate (eGFR) &lt;30 mL/min&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Severe coronary artery disease (left main stenosis, 3-vessel disease, proximal left&#xD;
             anterior descending stenosis, chronic total occlusion of major vessel)&#xD;
&#xD;
          -  Coronary disease where complete revascularization by PCI is considered difficult or&#xD;
             impossible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole Havndrup</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zealand Unviersity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole Ahlehoff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashkan Eftekhari</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital Skejby</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Kirk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rikke Sørensen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sune Ammentorp Haahr-Pedersen, MD</last_name>
    <phone>+45 38672267</phone>
    <phone_ext>+4530220889</phone_ext>
    <email>sunped01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels Thue Olsen, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gentofte University Hospital</name>
      <address>
        <city>Gentofte</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Thue Olsen, MD, PhD</last_name>
      <phone>+45 38 67 25 60</phone>
      <email>niels.thue.olsen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Sune Ammentorp Haahr-Pedersen</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Fractional flow reserve</keyword>
  <keyword>Optimal medical therapy</keyword>
  <keyword>Antianginal</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>1 year after publication</ipd_time_frame>
    <ipd_access_criteria>Upon request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

